CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Table: Targeting rituximab

Race for rituximab Targeting rituximab At least eight biosimilars of rituximab are on the market or in the clinic. Plans to develop four more have been announced by partners Chemo Lugano and Natco Pha...

Teva's biosimilar rituximab 'still active'

Teva Pharmaceuticals' biosimilar rituximab progam has not been terminated, or at least not yet. The generics giant told Scrip that it has "no new updates on rituximab, the project is active". This ca...

Rituximab Works for Older Mantle Cell Patients (CME/CE)

(MedPage Today) -- For older patients with mantle cell lymphoma, induction chemotherapy based on rituximab (Rituxan), followed by rituximab maintenance, offers an effective treatment, researchers repo...

Rituximab joint protective benefits capped

Study findings may help guide rituximab dosing regimens for patients with rheumatoid arthritis.

Intas launches biosimilar rituximab in India

Intas Pharmaceuticals Ltd. (Ahmedabad, India) launched Mabtas rituximab in India to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) alone or in combination with chemotherapy....

R-CHOP benefits older mantle-cell lymphoma patients

(HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintena...

HBV Screening Hit or Miss in Rituximab Users

ATLANTA (MedPage Today) -- At least in one academic medical center, half of cancer patients on rituximab (Rituxan) were not screened for hepatitis B virus infection as recommended, a researcher said h...

Rituximab for the Antiphospholipid Antibody Syndrome

Dr. Kevin Deane comments on a pilot study of rituximab for the treatment of antiphospholipid syndrome. Medscape Rheumatology

Rituximab for autoimmune blistering diseases: recent studies, new insights.

Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affe...

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.

Hepatitis B virus (HBV) reactivation is a well-known complication after rituximab therapy in patients with B cell lymphoma. Traditionally, hepatitis B surface antibody (anti-HBs) is a protective antib...

Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.

We conducted a retrospective survey to assess prescription practice, response rates to rituximab, and the predictive indicators for a response to rituximab therapy in patients with primary or secondar...

Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.

Background A few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Objective To analyse the efficac...

Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.

Treatment with a single dose of rituximab alone induced remission in a patient with relapsed minimal change nephrotic syndrome (MCNS). A 27-year-old man was given corticosteroid (prednisolone; PSL) an...